SCHEMBL3000616

SCHEMBL3000616

O=S(=O)(c1ccc(Br)cc1)N1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GBA1 P04062 2/20 0.48
LMNA P02545 2/20 0.46
RAB9A P51151 1/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 2/20 0.46
USP2 O75604 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.46
APAF1 O14727 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011602 0.91 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3014736 0.90 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3011282 0.89 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3020344 0.89 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL2998702 0.89 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1LMNAMEN1
SCHEMBL2998075 0.89 MEN1 (0.52) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3015782 0.89 GAA (0.50) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3011417 0.89 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3009893 0.89 KMT2A (0.54) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3013216 0.88 USP2 (0.44) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.